Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) FCF Margin (2021 - 2025)

InMed Pharmaceuticals has reported FCF Margin over the past 5 years, most recently at 289.72% for Q4 2025.

  • For Q4 2025, FCF Margin fell 6465.0% year-over-year to 289.72%; the TTM value through Dec 2025 reached 164.69%, down 1377.0%, while the annual FY2025 figure was 157.14%, 500.0% down from the prior year.
  • FCF Margin for Q4 2025 was 289.72% at InMed Pharmaceuticals, down from 143.52% in the prior quarter.
  • Over five years, FCF Margin peaked at 29.85% in Q2 2023 and troughed at 1728.88% in Q1 2022.
  • A 5-year average of 408.46% and a median of 164.96% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: skyrocketed 156865bps in 2023 and later plummeted -7605bps in 2024.
  • Year by year, FCF Margin stood at 1252.16% in 2021, then surged by 54bps to 577.52% in 2022, then surged by 74bps to 149.02% in 2023, then tumbled by -51bps to 225.07% in 2024, then fell by -29bps to 289.72% in 2025.
  • Business Quant data shows FCF Margin for INM at 289.72% in Q4 2025, 143.52% in Q3 2025, and 136.31% in Q2 2025.